MicroRNAs in cardiovascular disease

Gerasimos Siasos; Evanthia Bletsa; Panagiota K Stampouloglou; Evangelos Oikonomou; Vasiliki Tsigkou; Stavroula A Paschou; Konstantinos Vlasis; Georgios Marinos; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis

doi:10.1016/j.hjc.2020.03.003

MicroRNAs in cardiovascular disease

Hellenic J Cardiol. 2020 May-Jun;61(3):165-173. doi: 10.1016/j.hjc.2020.03.003. Epub 2020 Apr 17.

Affiliations

¹ Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: gsiasos@med.uoa.gr.
² Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
³ Department of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 32305497
DOI: 10.1016/j.hjc.2020.03.003

Abstract

Cardiovascular disease (CVD) remains the predominant cause of human morbidity and mortality in developed countries. Currently, microRNAs have been investigated in many diseases as well-promising biomarkers for diagnosis, prognosis, and disease monitoring. Plenty studies have been designed so as to elucidate the properties of microRNAs in the classification and risk stratification of patients with CVD and also to evaluate their potentials in individualized management and guide treatment decisions. Therefore, in this review article, we aimed to present the most recent data concerning the role of microRNAs as potential novel biomarkers for cardiovascular disease.

Keywords: Atherosclerosis; Biomarkers; Cardiovascular disease; MicroRNAs; Molecular cardiology.

Publication types

Review

MeSH terms

Biomarkers
Cardiovascular Diseases* / diagnosis
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / genetics
Humans
MicroRNAs* / genetics
Prognosis

Substances

Biomarkers
MicroRNAs